1. Home
  2. APLT

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Founded: 2016 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 502.8M IPO Year: 2019
Target Price: $11.00 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.84 EPS Growth: N/A
52 Week Low/High: $1.18 - $9.39 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -21.13% Revenue Growth (next year): 831.71%

Share on Social Networks:

Stock Insider Trading Activity of Applied Therapeutics Inc. (APLT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Hansard Adam APLT Chief Commercial Officer Mar 14 '24 Sell $5.39 48,871 $263,414.69 732,919 SEC Form 4
Funtleyder Leslie D. APLT Chief Financial Officer Mar 14 '24 Sell $5.39 28,727 $154,838.53 308,421 SEC Form 4
Kanter Stacy J. APLT Director Dec 1 '23 Buy $2.18 30,000 $65,367.00 63,000 SEC Form 4
Hansard Adam APLT Chief Commercial Officer Nov 30 '23 Sell $1.97 965 $1,901.05 381,790 SEC Form 4